| Primary |
| Asthma |
52.9% |
| Chronic Obstructive Pulmonary Disease |
19.4% |
| Drug Use For Unknown Indication |
9.1% |
| Bronchitis |
2.5% |
| Dyspnoea |
2.5% |
| Pneumonia |
2.5% |
| Cough |
1.7% |
| Asthma Prophylaxis |
1.2% |
| Emphysema |
1.2% |
| Respiratory Disorder |
1.2% |
| Asthma Exercise Induced |
0.8% |
| Hypersensitivity |
0.8% |
| Lung Disorder |
0.8% |
| Multiple Allergies |
0.8% |
| Anxiety |
0.4% |
| Chest Pain |
0.4% |
| Erectile Dysfunction |
0.4% |
| Fibromyalgia |
0.4% |
| Influenza |
0.4% |
| Intraocular Pressure Increased |
0.4% |
|
| Pharmaceutical Product Complaint |
13.0% |
| Product Quality Issue |
13.0% |
| Tremor |
8.0% |
| Vision Blurred |
6.0% |
| Wheezing |
6.0% |
| Pneumonia |
5.0% |
| Weight Decreased |
5.0% |
| Drug Ineffective |
4.0% |
| Dry Throat |
4.0% |
| Dyspnoea |
4.0% |
| Vomiting |
4.0% |
| Weight Increased |
4.0% |
| Insomnia |
3.0% |
| Laryngitis |
3.0% |
| Oral Candidiasis |
3.0% |
| Oropharyngeal Pain |
3.0% |
| Rash |
3.0% |
| Respiratory Disorder |
3.0% |
| Throat Irritation |
3.0% |
| Throat Tightness |
3.0% |
|
| Secondary |
| Asthma |
20.3% |
| Drug Use For Unknown Indication |
15.2% |
| Chronic Obstructive Pulmonary Disease |
13.9% |
| Cardiac Disorder |
7.6% |
| Antiemetic Supportive Care |
5.1% |
| Dyspnoea |
5.1% |
| Oesophageal Carcinoma |
5.1% |
| Benign Prostatic Hyperplasia |
3.8% |
| Hypertension |
3.8% |
| Acute Sinusitis |
2.5% |
| Antiplatelet Therapy |
2.5% |
| Bronchitis |
2.5% |
| Emphysema |
2.5% |
| Hyperlipidaemia |
2.5% |
| Anxiety |
1.3% |
| Bladder Disorder |
1.3% |
| Bronchitis Chronic |
1.3% |
| Gastrointestinal Disorder |
1.3% |
| Gastrooesophageal Reflux Disease |
1.3% |
| Hiatus Hernia |
1.3% |
|
| Tremor |
12.0% |
| Drug Ineffective |
8.0% |
| Dyspnoea |
8.0% |
| Product Quality Issue |
8.0% |
| Tonic Convulsion |
8.0% |
| Cardiac Failure |
4.0% |
| Dyspepsia |
4.0% |
| Dysphonia |
4.0% |
| Oral Candidiasis |
4.0% |
| Panniculitis |
4.0% |
| Rebound Effect |
4.0% |
| Renal Failure Acute |
4.0% |
| Sputum Discoloured |
4.0% |
| Throat Irritation |
4.0% |
| Thyroxine Free Increased |
4.0% |
| Urinary Tract Infection |
4.0% |
| Vomiting |
4.0% |
| Weight Decreased |
4.0% |
| Wheezing |
4.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
24.5% |
| Asthma |
18.2% |
| Chronic Obstructive Pulmonary Disease |
14.2% |
| Product Used For Unknown Indication |
5.8% |
| Depression |
4.1% |
| Hypertension |
4.1% |
| Dyspnoea |
3.0% |
| Hypersensitivity |
2.8% |
| Blood Cholesterol Increased |
2.7% |
| Pain |
2.7% |
| Emphysema |
2.5% |
| Arthritis |
2.2% |
| Back Pain |
1.8% |
| Crohn's Disease |
1.8% |
| Multiple Sclerosis |
1.8% |
| Cardiac Disorder |
1.6% |
| Diabetes Mellitus |
1.6% |
| Rheumatoid Arthritis |
1.6% |
| Type 2 Diabetes Mellitus |
1.6% |
| Coronary Artery Disease |
1.5% |
|
| Vomiting |
10.5% |
| Dyspnoea |
9.5% |
| Pneumonia |
7.4% |
| Urinary Tract Infection |
6.3% |
| Fistula |
5.3% |
| Myocardial Infarction |
5.3% |
| Pulmonary Embolism |
5.3% |
| Vision Blurred |
5.3% |
| Visual Acuity Reduced |
5.3% |
| Weight Increased |
5.3% |
| Skin Laceration |
4.2% |
| Spinal Column Stenosis |
4.2% |
| Weight Decreased |
4.2% |
| Pruritus |
3.2% |
| Renal Failure |
3.2% |
| Skin Discolouration |
3.2% |
| Thrombocytopenia |
3.2% |
| Thrombosis |
3.2% |
| Tremor |
3.2% |
| Troponin Increased |
3.2% |
|
